What effect does food have on the bioavailability of Cilostazol?

Cilostazol is a phosphodiesterase III inhibitor commonly used as an antiplatelet agent and for the treatment of intermittent claudication. The bioavailability of a medication refers to the proportion of the drug that enters the systemic circulation when administered and is available for therapeutic effect.

Food has a significant influence on the bioavailability of cilostazol. When taken with food, cilostazol's absorption increases, leading to higher plasma concentrations of the drug. This is particularly relevant because it means that patients will achieve better therapeutic outcomes if they take cilostazol in conjunction with meals. Food enhances the dissolution and absorption of the medication in the gastrointestinal tract, which is key to ensuring that the maximum amount of the active compound reaches the bloodstream.

Understanding this relationship is crucial for ensuring that patients adhere to the medication regimen effectively, optimizing its efficacy while minimizing potential side effects. In contrast, medications that have decreased bioavailability when taken with food would require different dosing instructions.